Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Secvenţă:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas Nr. : 159519-65-0
Formulă moleculară : C204H301N51O64
Greutate moleculară : 4492
Puritate (HPLC) : 98.0%min.
Aspect : Solid amorf alb până la aproape alb
Impuritate unică (HPLC) : 0.5%max
Compoziția aminoacizilor : ±10% din teoretic
Conținutul de peptide (N%) : ≥80,0%
Continut de apa (Karl Fischer) : ≤8,0%
Conținut de trifluoroacetat(HPIC) : ≤12,0%
DOMNIȘOARĂ (ESI) : Consistent
Bilanțul de masă : 95.0~105,0%
Nota : Gradul farmaceutic
Depozitare: Închis, de mai jos 2 ~ 8℃ conservare
Utilizare : Opțiune de tratament pentru pacienții care suferă de HIV/SIDA.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (HAN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
